TY - JOUR
T1 - Multicenter prospective validation study for international chronic ocular graft-versus-host disease consensus diagnostic criteria
AU - Ogawa, Yoko
AU - Dana, Reza
AU - Kim, Stella
AU - Jain, Sandeep
AU - Rosenblatt, Mark I.
AU - Perez, Victor L.
AU - Clayton, Janine A.
AU - Alves, Monica
AU - Rocha, Eduardo Melani
AU - Amparo, Francisco
AU - Seo, Kyoung Yul
AU - Wang, Yan
AU - Shen, Joanne
AU - Oh, Joo Youn
AU - Vanathi, Murugesan
AU - Nair, Sridevi
AU - Na, Kyung Sun
AU - Riemens, Anjo
AU - Sippel, Kimberly
AU - Soifer, Matias
AU - Wang, Shudan
AU - Trindade, Marilia
AU - Kim, Mee Kum
AU - Yoon, Chang Ho
AU - Yagi, Ryuichiro
AU - Hiratsuka, Ryo
AU - Ogawa, Mamoru
AU - Shimizu, Eisuke
AU - Sato, Yasunori
AU - Pflugfelder, Stephen
AU - Tsubota, Kazuo
N1 - Funding Information:
This research was supported by the grant for Global Clinical Research Center Program at Keio University from the Japanese Ministry of Health , Labor, and Welfare 2011, Japanese Ministry of Education , Science, Sports, and Culture, to Y.O.
Funding Information:
E.M.R. has a patent in Brazil (Patent: PI 0401186-4, title: "Formulation of Insulin eye drop for dry eye”, application number: PI 0401186-4, published in Revista de Propriedade Industrial 2356 on March 01, 2016, and patent application number: BR102015005856-0, title:”Microparticles of insulin, method of production and ophthalmic composition and use”. E.M.R. receive research grant form the Brazilian National Council for Scientific and Technological Development (CNPq) number: 1C 302355/2017-0.
Funding Information:
E.S. has grant from Japanese Ministry of Education, Science, Sports, and Culture 21K18394 and the Bristol Myers Squibb. The other authors received no financial support or other supportedthe authors have no financial interests that may create a potential conflict or the appearance of conflict of interest regarding this work.
Funding Information:
M.A. receives research grant from FAPESP number: 2021/04045-5.
Publisher Copyright:
© 2022
PY - 2022/10
Y1 - 2022/10
N2 - Purpose: To validate the international chronic ocular graft-versus-host disease (GVHD) diagnostic criteria (ICCGVHD) compared to the National Institute of Health diagnostic criteria 2014 (NIH2014) for chronic ocular GVHD. Methods: Between 2013 and 2019, the study enrolled 233 patients with or without chronic ocular GVHD combined with the presence or absence of systemic chronic GVHD in an internationally prospective multicenter and observational cohort from 9 institutions. All patients were evaluated for four clinical parameters of ICCGVHD. Results: The relation between the ICCGVHD score (0-11) and NIH2014 eye score (0–4) was relatively high (r = 0.708, 95% CI: 0.637–0.767, p < 0.001). The sensitivity and specificity of ICCGVHD for NIH 2014 for 233 patients were 94.3% (95% CI: 89.6%–98.1%) and 71.7% (95% CI: 63.0–79.5%), respectively (cutoff value of the ICCGVHD score = 6). The positive predictive value was 77.1% (95% CI: 71.1%–82.1%), and the negative predictive value was 87.0% (95% CI:81.6–92.5%). For the patients with systemic GVHD (n = 171), the sensitivity and specificity were 94.2% and 67.2%, respectively (ICCGVHD-score cutoff value = 6). By receiver operating characteristic (ROC) curve analysis, the area under the curve (AUC) was 0.903 (95% CI: 0.859–0.948). For patients without systemic GVHD (n = 62), the sensitivity and specificity were 100% and 76.7%, respectively (ICCGVHD-score cutoff value = 6). The AUC was 0.891 (95% CI 0.673–1.000). Conclusions: Good sensitivity, specificity, predictive value and correlation were found between ICCGVHD and NIH2014. ICCGVHD scores ≥6 can be useful to diagnose ocular GVHD with or without systemic GVHD for clinical research.
AB - Purpose: To validate the international chronic ocular graft-versus-host disease (GVHD) diagnostic criteria (ICCGVHD) compared to the National Institute of Health diagnostic criteria 2014 (NIH2014) for chronic ocular GVHD. Methods: Between 2013 and 2019, the study enrolled 233 patients with or without chronic ocular GVHD combined with the presence or absence of systemic chronic GVHD in an internationally prospective multicenter and observational cohort from 9 institutions. All patients were evaluated for four clinical parameters of ICCGVHD. Results: The relation between the ICCGVHD score (0-11) and NIH2014 eye score (0–4) was relatively high (r = 0.708, 95% CI: 0.637–0.767, p < 0.001). The sensitivity and specificity of ICCGVHD for NIH 2014 for 233 patients were 94.3% (95% CI: 89.6%–98.1%) and 71.7% (95% CI: 63.0–79.5%), respectively (cutoff value of the ICCGVHD score = 6). The positive predictive value was 77.1% (95% CI: 71.1%–82.1%), and the negative predictive value was 87.0% (95% CI:81.6–92.5%). For the patients with systemic GVHD (n = 171), the sensitivity and specificity were 94.2% and 67.2%, respectively (ICCGVHD-score cutoff value = 6). By receiver operating characteristic (ROC) curve analysis, the area under the curve (AUC) was 0.903 (95% CI: 0.859–0.948). For patients without systemic GVHD (n = 62), the sensitivity and specificity were 100% and 76.7%, respectively (ICCGVHD-score cutoff value = 6). The AUC was 0.891 (95% CI 0.673–1.000). Conclusions: Good sensitivity, specificity, predictive value and correlation were found between ICCGVHD and NIH2014. ICCGVHD scores ≥6 can be useful to diagnose ocular GVHD with or without systemic GVHD for clinical research.
KW - Chronic ocular graft-versus-host disease
KW - Dry eye disease
KW - International chronic ocular GVHD consensus Criteria
KW - NIH diagnostic Criteria 2014
UR - http://www.scopus.com/inward/record.url?scp=85138620558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138620558&partnerID=8YFLogxK
U2 - 10.1016/j.jtos.2022.09.002
DO - 10.1016/j.jtos.2022.09.002
M3 - Article
C2 - 36130695
AN - SCOPUS:85138620558
VL - 26
SP - 200
EP - 208
JO - Ocular Surface
JF - Ocular Surface
SN - 1542-0124
ER -